1. Home
  2. EAF vs NKTX Comparison

EAF vs NKTX Comparison

Compare EAF & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GrafTech International Ltd.

EAF

GrafTech International Ltd.

HOLD

Current Price

$9.29

Market Cap

221.9M

Sector

Energy

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$3.34

Market Cap

247.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EAF
NKTX
Founded
1886
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
221.9M
247.4M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
EAF
NKTX
Price
$9.29
$3.34
Analyst Decision
Hold
Strong Buy
Analyst Count
5
4
Target Price
$11.75
$11.33
AVG Volume (30 Days)
254.0K
1.0M
Earning Date
05-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
$504,134,000.00
N/A
Revenue This Year
$4.25
N/A
Revenue Next Year
$12.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$1.63
52 Week High
$20.32
$3.65

Technical Indicators

Market Signals
Indicator
EAF
NKTX
Relative Strength Index (RSI) 61.03 66.48
Support Level $7.65 $1.88
Resistance Level $9.78 $3.65
Average True Range (ATR) 0.78 0.28
MACD 0.00 0.01
Stochastic Oscillator 76.88 67.15

Price Performance

Historical Comparison
EAF
NKTX

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: